Search
Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive profile in humans could signal that SH2's time has arrived
CEO Nancy Whiting walks us through the biology of SH2 and the potential breadth of it as a therapeutics approach (there are 120 SH2 domains). The lead STAT6 program is in healthy volunters, and the company is also working on a BTK. Plus, her thoughts on HHS's new initiative to speed up clinical trials in the United States. Chapters Her thoughts on HHS's new trials initiative - 2:39 Recludix's work on SH2 - 6:51 Coverage brought to you by
Jun 26
Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK
President & CEO Nancy Whiting discusses the historical difficulties in drugging SH2, and describes the company's discovery platform that enables it today. A STAT6 program is already dosing in the clinic, and Sanofi has a partnership on it. Plus, a BTK, and a recent financing that Lilly participated in.
Mar 10
.png){kind=logo}